The role of the immune system in the physiopathology of osteoporosis

Valentina Cagnetta  
Vittorio Patella

Department of Clinical Methodology and Surgical Techniques, Orthopedics Section II, University of Bari “Aldo Moro”, Bari, Italy

Address for correspondence:  
Valentina Cagnetta, MD  
Department of Clinical Methodology and Surgical Techniques, Orthopedics Section II  
University of Bari "Aldo Moro"  
Piazza Giulio Cesare, 11  
70100 Bari, Italy  
Phone/Fax: +39 080 5592719  
E-mail: valentinacagna@hotmail.it

Summary

The close anatomical relationship between the immune system, estrogen deficiency and bone loss has been recognized for centuries but the existence of a functional relationship has emerged only recently. The role of the immune system in the development of senile osteoporosis, which arises primarily through the effects of estrogen deficiency and secondary hyperparathyroidism, is slowly being unraveled. This review focuses on the evidence that links immune cells, inflammation, cytokine production and osteoclast formation and their activity. The under standing of the interplay of inflammation and osteoclast can lead to the development of new drugs for prevention and treatment of bone loss.

KEY WORDS: osteoporosis; immune system; osteoclast; cytokines; T cells; B cells.

Introduction

Bone provides structural integrity for the body, it is the site of hematopoiesis and it is a storehouse for calcium and phosphorus (1). Likewise, the immune system provides organism with protection from invading pathogens (2). Multiple overlapping and interacting mechanisms have evolved to regulate both systems. The osteoblasts are critical regulator of the hematopoietic stem cell niche from which all blood and immune cells derive, the osteoclast appears to share a common origin with the myeloid precursor cells that also gives rise to macrophages and myeloid dendritic cells. Multiple soluble mediators of immune cell function including cytokine, chemokines and growth factor also regulate osteoblast and osteoclast activity (3). Inflammatory disease characterized by systemic and local bone loss is an interesting field with which to explore the relationship between activation of the immune system and bone remodeling. Estrogen deprivation induces bone loss. At the same time estrogens are well known regulators of the immune system and T cell functions (4, 5). Thus the immune system can be suggested as a key interface between estrogen deprivation and bone metabolism. This review aims to summarize the evidences linking immune activation and bone loss with particular attention to humans.

Estrogen loss and immune system

The immune system plays a critical role in the pathophysiology of postmenopausal osteoporosis. Estrogen deficiency induces bone loss and at the same time estrogen mild increase in production of proinflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, systemically and locally, which promotes osteoclastogenesis in the bone marrow because they are well known regulators of the immune system and T cell function (6). The most important cytokine in the context of estrogen deficiency-induced bone loss has been shown to be TNF-alpha produced by bone marrow T-lymphocytes that are stimulated through a complex mechanism involving antigen-presenting cells and various cytokines including IL-7, IFN-gamma, and TGF-beta. Proinflammatory cytokines also suppress osteoblastogenesis, while the crosstalk between T-lymphocytes and marrow stromal cells regulates the osteoclastogenic activity of the latter. Estrogen plays a fundamental role in skeleton growth and bone remodeling and the role of estrogen in the regulation of immune function has been demonstrated in animals and humans: immune cells are more responsive to antigenic stimuli in hormone replacement therapy users than non-users (7).

D’Amelio et al. demonstrated that T cells from post-menopausal women show blunted reaction to immune stimulation in respect to pre-menopausal healthy women. At baseline, T cells are more active than in healthy post- and pre-menopausal controls: this implies their greater ability to produce RANKL and TNF-alpha, thus inducing OC formation and activity (8). They have also demonstrated that OC formation is abolished in T cell-depleted PBMC cultures and this phenomenon is reversed only by the addition of M-CSF and RANKL in cultures.

Estrogen withdrawal up-regulates TNF-alpha production by T cells through a complex pathway involving the thymus and bone marrow. In the bone marrow, ovariectomy promotes T cell activation by increasing antigen presentation by macrophages and DCs (9, 10). The relevance of TNF in the mechanism by which estrogen causes bone loss has been demonstrated using multiple animal models. For example in the murine model ovariectomy increases the number of bone marrow T cell-producing TNF (11-13). The effects of ovx on antigen presentation and the resulting changes in T-cell activation, proliferation, and lifespan are explained by a stimulatory effect of ovx on the expression of the gene-encoding class II transactivator (CIITA). The product of the CIITA gene is a non-DNA binding factor that functions as a transcriptional co-activator, when recruited to the MHCII promoter by interaction with promoter-bound factors (14). CIITA expression is required and sufficient for the stimulation of antigen presentation in bone marrow monocytes with the final effect of up-regulation of expression of MHCII on macrophages (9, 15, 16). This process proved essential since data show that ovariectomy induces rapid bone loss in wild type mice but failed to do so in TNF-alpha-deficient [TNFalpha (-/-)] mice and in T cell-deficient nude mice.
Moreover, RANKL-expression on lymphocytes and marrow stromal cells is significantly elevated during estrogen deficiency in humans and correlates directly with increases in bone resorption markers and inversely with serum estrogen levels (17). Estrogen withdrawal has effects on the B cell compartment. B cells have recently been directly implicated in the regulation of bone resorption as they represent a major source of OPG. Historically, an extensive in vitro data set has led to the widely accepted precept the major source of BM OPG is the OB and/or its immediate precursor, the BM SC. More recent data have show that B cell are more likely the dominant producers of OPG in the bone microenvironment in vivo (18). This conclusion was arrived at following an extensive series of investigations into the bone phenotype of B cell Knockout (KO) mice (18). B cell KO mice present at baseline with an osteoporotic phenotype (19), a consequence of enhanced osteoclastic bone resorption. Examination of the RANKL/OPG ratio B cell KO bone identified a specific deficiency in OPG mRNA and in the protein expression (18). Reconstitution of young B cell KO mice with B cell by means of adoptive transfer, completely rescued mice from development of osteoporosis, by normalizing OPG production (18). B cells play an important role in regulating basal OC formation and in regulating bone oestogenesis.

Cytokines and OC formation

OCs arise by cytokine-driven proliferation and differentiation of mononuclear precursors that circulate within the hematopoietic cell pool. The minimal essential cytokines required for OC formation under basal conditions are RANKL and M-CSF. The Receptor Activator of NFkB Ligand (RANKL) and Macrophage Colony Stimulating Factor (M-CSF) are produced by bone marrow stromal cells (20), OBs (21) and activated T cells (2, 22). The co-stimulation by RANKL and M-CSF is essential for the differentiation of monocytes into OCs (23, 24). M-CSF induces the proliferation of OC precursors, differentiation and fusion of mature OCs and increases the survival of mature OCs. RANKL promotes the differentiation of OC precursors into fully mature multinucleated OCs and stimulates the capacity of mature OCs to resorb bone. RANKL is a member of the TNF superfamily, present both as a transmembrane and in secreted form. It binds to its physiological receptor RANK expressed on the surface of OC lineage cells. Its action is opposed by osteoprotegerin (OPG), a neutralizing soluble receptor RANK expressed on the surface of OC lineage cells. RANKL promotes the differentiation of OC precursors (32). TNF and IL-1 engage initially distinct signaling pathways that converge with the activation of the transcription factor NF-kB and the stimulation of the mitogen-activated protein kinase (MAPK) system. Thus, the combined effect of these two cytokines provides a potent signal to osteoclastogenesis, inhibition of OB function, and regulation of the lifespan of skeletal cells. An important yet controversial OC-regulating factor is interferon (IFN)-gamma. This cytokine has an antiosteoclastogenic effect in vitro (33) and in vivo in nude mice models (34, 35). Studies in humans indicate an increased level of IFN-gamma during estrogen deficiency (36, 39), in inflammatory and rheumatoid arthritis with bone erosions (37, 38). Moreover, data from randomized controlled trials have shown that IFN-gamma does not prevent bone loss in patients with RA (39, 40) nor the bone wasting effect of cyclosporin A (41). These data are explained by the finding that IFN-gamma influences OC formation both via direct and indirect effects (36). It directly blocks OC formation targeting maturing OC (42) and also induces antigen presentation and thus T cell activation. When IFN-gamma levels are increased in vivo, activated T cells secrete pro-osteoclastogenic factors and this activity offsets the anti-osteoclastogenic effect of IFN-gamma (43).

Another cytokine relevant for OC formation is interleukin-7 (IL-7). Some studies have demonstrated that IL-7 promotes osteoclastogenesis by up-regulating T cell-derived osteoclastogenic cytokines including RANKL (44, 45) and that the production is up-regulated by estrogen deficiency. In vivo IL-7 blockade is proven to suppress T cell expansion and TNFalpha and IFN-gamma production, preventing bone loss due to estrogen deprivation (46, 47).

In healthy humans, the expression of IL-7 receptors on T lymphocytes is strictly related to their ability to induce OC formation from peripheral blood mononuclear cells (48).

Osteoporosis and inflammation

Several inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, celiac disease, cystic fibrosis and chronic obstructive pulmonary disease have been associated to bone resorption. The link between osteoclast, macrophage colony stimulating factor and pro-inflammatory cytokines, especially TNFalpha and IL-1, explain the association between inflammation and osteoporosis. The activation of T cells in autoimmunity or during infection increases RANKL production and promote osteoclastogenesis. The process can be reverted by the administration of OPG in several pathological conditions such as RA and periodontitis (49). Particularly in autoimmune arthritis, T cell subsets have been examined and Th17 cells, a specialized inflammatory subset, have been identified as responsible for osteoclastogenesis regulation. An inflammatory milieu induces naive T cells to differentiate into Th17, capable to produce RANKL, TNFalpha and IL-17, a cytokine that increases RANKL expression by OBs (50).

Researchers recently began to investigate a possible direct role of dendritic cells (DC) in inflammation related bone damage. DCs are known for their role of antigen presenting cells (APCs) and do not appear to play a role in bone homeostasis in non-pathological conditions, but some data suggest that DC could act as DC precursors in an inflammatory milieu, transforming into DC-derived OC according to phenotypic and functional characterization.
The role of the immune system in the physiopathology of osteoporosis

studies. Moreover, DCs modulate T cell activity through RANK/RANKL pathway and other cytokines associated with osteoclastogenesis (51-53). There is a lack of definitive evidence about the physiological relevance of this phenomenon in vivo but DCs could act as an osteo-immune interface, contributing to bone loss in inflammatory diseases.

On the other hand, investigations have focused on the role of B-lymphocytes in periodontal inflammation. The host immune response is partly responsible for the bone destruction in cases of periodontitis and the RANK/RANK/OPG signalling axis is important both in bone and immune system communication. Data suggest that B-lymphocyte involvement in the adaptive immune response contributes to bone resorption by up-regulating of RANKL expression through Toll-like receptor pathways. These data align with the known ability of T cells to produce RANKL in the presence of immunostimulants, and to induce osteoclastogenesis (54). Other studies focused on psoriatic arthritis, a chronic inflammatory disease characterized by joint erosions mediated by OCs. These OCs seem to derive from CD14+CD16+ circulating monocytes, present at higher level in patients than in healthy controls when exposed to OC-promoting microenvironment (M-CSF and RANKL). OCs do not derive from this population in healthy controls; thus CD16 can be considered a marker of OC precursors in arthritis (55).

Conclusion

Remarkable progress has been made using animal models to elucidate the cellular and molecular mechanisms governing homeostasis, the cross-talk between the immune system and bone leading to bone loss due to dysregulation of T lymphocyte function. If these relationships are equally relevant in humans as they are in rodents, osteoporosis may soon become classified as an inflammatory or autoimmune condition and postmenopausal osteoporosis should be regarded as an inflammatory disorder sustained by a chronic mild decrease in T cell tolerance. And if these discoveries can be translated into humans, a door will be opened to exciting new potential therapeutic agents and strategies that target the bone-immune interface to ameliorate bone disease in numerous osteoporotic conditions. However, despite extensive cross-regulation between bone metabolism and the immune system, a number of questions remain, such as the mechanisms by which these systems cross-regulate. The fresh insights gained from the physiological relevance of this phenomenon in vivo but DCs could act as an osteo-immune interface, contributing to bone loss in inflammatory diseases.

However, despite extensive cross-regulation between bone metabolism and the immune system, a number of questions remain, such as the mechanisms by which these systems cross-regulate. The fresh insights gained from the physiological relevance of this phenomenon in vivo but DCs could act as an osteo-immune interface, contributing to bone loss in inflammatory diseases.

References

3. Horowitz MC, Lorenzo J. Local regulators of bone: IL-1, TNF, and lymphotxin, interferon gamma, IL-8, IL-10, IL-4, the LIF/L-6 family and additional cytokines. Principals of bone biology J. Academic Press. San Diego, California, USA. 1996:961-977.


